Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

Lebanon's Eli Lilly and Co. employees recently donated to the Caring Center more than 530 pounds of food which according to ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Eli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat ...

The retail properties are part of a greater development that will also include a luxury apartment complex and a Bee Safe ...